⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 29, 2026Alimentary Pharmacology & TherapeuticsOpen Access

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Jörn M. Schattenberg Jesús M. Bañales Gideon Hirschfield P. Trivedi Edward E. Cable Charles A. McWherter Andrew N. Billin Daria B. Crittenden Grant R. Budas

View Full Paper

Ask AI

Bookmark

Share

Key Points

The article reviews the role of peroxisome proliferator-activated receptors in primary biliary cholangitis and emphasizes the need for isoform-specific investigations.
Review of existing literature on PPAR agonists and their isoform selectivity.
Analysis of efficacy and safety profiles of different PPAR agonists.
Identifies the importance of isoform selectivity in the effectiveness of PPAR agonists.
Highlights the need for research on isoform-specific mechanisms related to symptom relief.

Implication

Review Article examines PPAR agonists’ effectiveness in alleviating symptoms in primary biliary cholangitis, suggesting areas for further research.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schattenberg et al. (2026) studied this question.

synapsesocial.com/papers/69ccb6e416edfba7beb889ae https://doi.org/10.1111/apt.70598

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis2025 · 2 citations
2Randomized Controlled Trial Evidence on Peroxisome Proliferator‐Activated Receptor (PPAR) Agonists in Primary Biliary Cholangitis: A Systematic Review and Meta‐Analysis2025 · 1 citations
3Letter: Therapeutic Targeting of <scp>PPARs</scp> in <scp>PBC</scp> —Additional ConsiderationsRCT · 2026 · 1 citations
4Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis and Other Liver Diseases: Mechanisms, Clinical Evidence, and Future DirectionsHuman Clinical Trial · 2026
5Emerging Therapeutics for Primary Biliary Cholangitis2025 · 1 citations